St. Cloud Surgical Center is First ASC in U.S. to Utilize Xenex Germ-Zapping Robot to Disinfect Operating Rooms & Enhance Patient Safety more

4 cheap small cap stocks I’ve got my eye for Christmas more

Southern Biologics Network Established to Create Biologics Faster and Less Expensively more

Morningside Ministries at the Manor is the First Skilled Nursing Facility in Texas to Protect Residents with Xenex Germ-Zapping Robot more

RBA to cut rates in 2015: Still want to invest in term deposits? more

Can robots help stop the Ebola outbreak? more

Robots Help Fight Ebola more

South Florida Hospital Unveils Ebola-Zapping Robot more

Sonoma Valley Hospital uses robot to kill germs more

Robots go to war against Ebola more

New iTraumaCare CEO to pursue big growth more

UAB and SRI have plans to spinoff more success more

Launch of Galderma's new acne products more

iTraumaCare’s new CEO to help company secure new funding more

U.S. Air Force Hospital Langley Adds Xenex Ebola-Zapping Robot to Inventory more

Forthcoming Acne Treatment Made With Exclusive (And Sustainable) East Indian Sandalwood Oil more

Sonoma Valley Hospital Acquires Xenex Germ-Killing Robot to Enhance Patient Safety more

Robot fights germs at Sharp Chula Vista Medical Center more

Xenex updates protocols for germ-zapping robots in response to Ebola threat more

How do we get rid of the endotoxins? Birmingham's  has the solution more

Medical Device ® Positions New Leader for Next-Level Growth more

The Xenex robot at South Shore Hospital featured on an Xploration Earth more

Germ-zapping robot Gigi sets its sights on Ebola more

Morningside Ventures leads a Series B round for DNAtrix more

StemBioSys secures new research space at BioBridge Global more

Birmingham's Soluble Therapeutics acquires Seattle company Dilyx Biotechnology more

Company invents germ-zapping robot more

Xenex Congratulates Houston Cancer Hospital more

Australian grown Indian Sandalwood timber attracts lucrative Asian markets more

DNATRIX ANNOUNCES TREATMENT OF FIRST PATIENT WITH DNX-2401 more

Targeted Technology raises more than $40 million more

Reducing Healthcare Associated Infections (HAIs): Not All UV Light is the Same more

Bluegrass Vascular Technologies Names Dr. Gabriele Niederauer President And CEO more

Three Birmingham companies recognized in PwC report more

Former Kinetic Concepts Inc. CEO to lead StemBioSys more

International dermatology company Galderma confirmed more

AUSTRALIAN Sandalwood producer TFS Corporation will supply oil more

San Antonio luring biotech firms with venture capital more

Biotech firm secures nearly $5 million in funding, is relocating to San Antonio more

Birmingham is on the front lines of medical research: take a look at this incredible biotech startup more

Germ-Zapping Robots Fight C. diff and MRSA at Mercy Health Saint Mary's more

Milford hospital enlists robots in war against infections more

Xenex Testifies About UV Room Disinfection Technology Effectiveness to U.S. House of Representatives more

Western Pa. hospitals test robot using ultraviolet rays to kill bacteria more

Xenex Demonstrates UV Room Cleaning System’s Effectiveness in Reducing Hospital Acquired Infections

San Antonio-based Xenex Disinfection Services, a leader in ultraviolet environmental disinfection systems, last week demonstrated the effectiveness of its germ-zapping robot in reducing healthcare associated infection (HAI) rates at U.S. hospitals and Veterans Administration facilities. The presentation, entitled “Technology for Patient Safety at Veterans Hospitals,” was made before the U.S. House of Representatives Committee on Science, Space, and Technology; the Subcommittee on Research and Technology; and the Subcommittee on Oversight.

A study recently published by the American Journal of Infection Control showed a 20% decrease in hospital-acquired infections rates during a 22-month period where ultraviolet environmental disinfection was implemented, compared with the 30-month period before the UVD was applied. The authors of the study concluded that the use of UVD as an adjunct to routine discharge cleaning of contact precautions rooms was feasible and temporally associated with a significant decrease in hospital-acquired infections. Last week’s presentation focused precisely on the results of this and other similar studies.

The purpose of the hearing was to assess the potential benefits of new technologies in the prevention of HAIs. Considering that HAIs are the most common complication of hospital care, with the Centers for Disease Control estimating that 1.7 million HAIs per year cause up to 99,000 deaths annually in the U.S., Xenex’s technology helps to meet the need to approach 100% prevention of HAIs as the larger challenge of all U.S. hospitals.

The company presented the results of its patented pulse xenon UV disinfection system, which has been repeatedly shown to integrate smoothly into hospital cleaning operations because of its speed and ease of use. The portable system uses pulsed xenon ultraviolet light to destroy viruses, bacteria and bacterial spores in the patient environment without contact or chemicals. Furthermore, the Xenex system will disinfect dozens of rooms per day, so hospitals use the robot continuously to reduce contamination levels throughout their facilities.

At the hearing, Xenex CEO Morris Miller recalled that six peer-reviewed studies have been published supporting the efficacy of the company’s technology, including three where Xenex customers reported significantly reduced HAI rates after implementing the Xenex robot for room disinfection. Taking up to this challenge, he reinforced, quoted by the Herald Online, the Congress should have an opportunity to significantly improve the patients’ health, by promoting policies that accelerate the implementation of these technologies. back

TFS flags record full-year profit more

Sweet scented sandalwood flavour of month more

House committee looks for new technology in Veterans Affairs hospitals more

FDA grants fast track status to drug DNX-2401 for recurrent Glioblastoma more

CEO shakeup at San Antonio biotech company StemBioSys more

First harvest to be completed in June more

BiO2 Medical Enrolls Subjects in the New U.S. FDA Early Feasibility Pilot Study for the Angel® Catheter more

San Antonio biotech firm readies skin treatment for distribution more

ViroXis Gets Approval To Initiate FDA Phase 2 Study For Molluscum Contagiosum more

Medical technologies conference announces speaker lineup more

Australian sandalwood sells for millions more

Sandalwood exports as good as gold more

Santalis Pharmaceuticals Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize OTC Dermatology Products more

ViroXis Corporation Signs Exclusive License Agreement with Global Pharmaceutical Company to Commercialize an OTC Dermatology Product more

DNAtrix Awarded $10.8 Million Grant by the Cancer Prevention and Research Institute of Texas more

ViroXis Corporation Achieves Key Clinical Milestones more

There are growing concerns about the threat of an antibiotic crisis caused by the spread of drug-resistant superbugs. Those concerns could result in more